BLAINJECTIONINJECTABLEPriority Review
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TIVDAK (tisotumab vedotin) is an antibody-drug conjugate (ADC) approved by the FDA in September 2021 for the treatment of cervical cancer. It works by targeting tissue factor (TF) on cancer cells and delivering a cytotoxic payload to induce cell death. This mechanism represents a novel approach in oncology for patients with limited therapeutic options.
$0.704MPart D
PeakEarly commercial phase with moderate adoption signals; brand teams are focused on market penetration in second-line cervical cancer.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (12)
Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva
Started Nov 2026
28 enrolled
Vulvar CarcinomaRecurrent or Metastatic Vulvar CancerSquamous Cell Carcinoma Vulva
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Started May 2025
100 enrolled
Cervical Cancer
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
Started Jun 2023
19 enrolled
Solid Malignancies
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Started Feb 2021
502 enrolled
Cervical Cancer
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
Started Mar 2019
98 enrolled
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Worked on TIVDAK at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.